Results 231 to 240 of about 89,305 (304)
Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition. [PDF]
Front ImmunolZhu X, Cui X, Yu H, Xu J, Chen X, Ren X, Wei X, Chen S, Wang Y, Fei L, Xie B, Li M, Li X, Jia H, Feng Y, Xia S, Chen L, Cheng Y, Zhang L, Li H, Zhu X, Zhan Y. +21 moreeuropepmc +1 more sourceHuman KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human‐Mouse KIT
Allergy, Volume 81, Issue 4, Page 1269-1272, April 2026.Hye‐Sook Kwon, Song Eun Lee, Ajay Sharma, Minyoung Youn, Charles A. Chang, Andrew Wells, Andrea R. Romo, Allison Ji, Sara Ratia, Sambidhan Kattel, Revati Nerkar, Karl Meneses, Cheryl Kwan, Mang Yu, Wendy W. Pang +14 morewiley +1 more sourceClinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.
Health Technol AssessBryant A, Lecouturier J, Orozco-Leal G, Brocklebank V, Carnell S, Chadwick TJ, Dunn S, Johnson SA, Kavanagh D, Kennedy CA, Malina M, Montgomery EK, Muirhead CR, Oluboyede Y, Vale L, Weetman C, Kwan Soon Wong E, Woodward L, Sheerin NS. +18 moreeuropepmc +1 more source
